NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- Ortec International, Inc. (OTC Bulletin Board: OTCI - News), a company focused on advancing regenerative medicine through the development of cellular technology and advanced biomaterial products, has received notification from the U.S. patent office that claims contained in its second patent application related to its Haptides(TM) technology platform, have been allowed. The newly granted claims broaden the claims previously granted to Ortec by the United States Patent Office in June 2006. The patents incorporating the claims contained in both Notices of Allowance are expected to be issued within the next six months.
